At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Pulmatrix, Inc. (NASDAQ: PULM) has been granted U.S. patent 9,119,778, for the Company's underlying iSPERSE™ inhaled dry powder technology. The patent broadly covers small, dense and dispersible...
Pulmatrix, Inc., (NASDAQ: PULM) reports second quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. "During the second...
Pulmatrix, Inc., (NASDAQ: PULM) will webcast an investor presentation August 6, 2015 at 10:45 am EDT. As part of the presentation, Robert Clarke, Chief Executive Officer, will review Pulmatrix's...
Pulmatrix, Inc. (NASDAQ: PULM) has been granted two patents from the U.S. Patent and Trademark Office (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352), which cover the composition of matter...
Dear Fellow Shareholders, The Pulmatrix management team and I would like to thank our founding institutional shareholders for their continued support and investment. Additionally, we want to...